Barclays PLC Morpho Sys Ag Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Morpho Sys Ag stock. As of the latest transaction made, Barclays PLC holds 14 shares of MOR stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 14 -0.0%

Holding current value

Previous $1,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$0.0 - $18.96 $0 - $265	14 New	14 $1,000
Q1 2023 May 04, 2023	SELL	$3.56 - $5.22 $32 - $46	-9 Reduced 75.0%	3 $0
Q4 2022 Feb 13, 2023	BUY	$3.21 - $5.74 $38 - $68	12 New	12 $0
Q4 2021 Feb 14, 2022	SELL	$9.08 - $12.45 $363 - $498	-40 Closed	0 $0
Q3 2021 Nov 09, 2021	BUY	$11.76 - $19.51 $470 - $780	40 New	40 $0
Q2 2021 Aug 13, 2021	SELL	$18.95 - $23.95 $3,145 - $3,975	-166 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$21.56 - $30.66 $3,578 - $5,089	166 New	166 $4,000

Others Institutions Holding MOR

# of Institutions

Shares Held

1.8M

Call Options Held

Put Options Held

14.7K

View Full List

About MorphoSys AG

Ticker MOR
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 136,614,000
Description
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...

More about MOR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account